Boehringer Ingelheim announced today that the FIBRONEER™-ILD trial met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 versus placebo.
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...
Keychron's B1 Pro punches way above its price tag, offering comparable features and performance to the Logitech MX Keys and ...
The screen has a new auto-brightness feature, as well as five levels you can manually select from. At 620 nits peak, it's not ...
Q4 2024 Earnings Call Transcript February 6, 2025 Operator: Good day and thank you for standing by. Welcome to the Suncor ...
Q4 2024 Earnings Conference Call February 6, 2025 2:00 AM ETCompany ParticipantsRonojoy Banerjee - Communications ...
Even with the increased overlap from digital transformation, understanding the distinction between marketing and advertising ...
Shannyn Schroeder on MSN4h
The Good Enough Strategy: How Satisficing Can Simplify Your Life and Reduce StressHave you ever felt crushed by the endless need to make the “perfect” choice? You're not alone. Decision-making can be ...
Excel conditional formatting made easy! Learn formulas, advanced techniques, and troubleshooting tips to enhance your data ...
Open communication has been a central part of fostering innovation, this is threatened in the modern digital age.
While Intel Foundry is the future growth driver, it will take time because of the long product cycle. Read why INTC stock is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback